What is it?
What Fisetin is
2Fisetin is a naturally occurring flavonol found in small amounts in foods such as strawberries and other plants, but most supplement listings are isolated or standardized extracts rather than whole-food servings. Its current research interest is less about acute stimulation and more about senolytic, antioxidant, inflammatory, and cellular-aging pathways.
Names, aliases and forms
Mechanisms of action
Senolytic research context
4Preclinical work identifies Fisetin among compounds that can influence senescent-cell pathways. Translation reviews emphasize that senolytic effects depend on cell type, context, dose, and intermittent exposure, so this mechanism should not be simplified into a guaranteed human longevity effect.
Antioxidant and inflammatory pathways
2Reviews describe Fisetin as a multitarget flavonol that interacts with oxidative-stress and inflammatory pathways in experimental systems. Those mechanisms are useful for explaining research interest, but they are not direct proof of cognitive, mood, or disease outcomes in supplement users.
Potential effects and evidence map
Fisetin has mechanistic, animal, and review-level evidence around antioxidant, inflammatory, senolytic, and cellular-aging pathways. Human evidence is sparse: a small healthy-volunteer study measured formulation-specific plasma pharmacokinetics, and a small placebo-controlled, pseudo-randomized crossover study in Gulf War Illness did not reduce symptom severity versus placebo. A completed knee-osteoarthritis study and other trial records are condition-specific. These sources do not establish human nootropic, longevity, or general healthy-aging benefits.
Fisetin is studied as a senolytic and cellular-aging candidate, but most supportive evidence is preclinical and does not prove human brain or longevity benefits.
Direct human nootropic trial evidence was not found for memory or learning benefits from Fisetin supplementation.
Posted results from a small knee-osteoarthritis trial and other condition-specific trial records do not establish a Fisetin benefit for healthy adults or general physical performance.
Mood or wellbeing claims are not supported by direct human Fisetin evidence found for this page.
Typical dosages and timing
The AFFIRM-LITE study protocol uses this oral amount for 2 consecutive days in its enrolled population; it is not a generic consumer recommendation.
This short, population-specific protocol window is study context, not a daily supplement recommendation.
Compare the exact ingredient and labelled mass rather than capsule count alone. A standardized extract and isolated Fisetin powder are not interchangeable unless the label identifies the amount of Fisetin.
Timing & effect horizon
Safety, side effects and risk profile
Healthy-adult cognitive and longevity efficacy, ordinary daily-use dosing, cycle timing, and long-term outcomes remain uncertain.
The AFFIRM-LITE protocol lists holds for certain CYP-sensitive medicines, some antimicrobials, and acid-reducing medicines as population-specific precautionary flags.
Pregnancy and lactation have not been adequately studied in the cited human research.
A small, condition-specific crossover trial reported sparse mild-to-moderate self-reported lower-GI upset, GERD, and nausea across placebo and Fisetin phases; it does not establish a Fisetin-specific causal risk or a rate for healthy users.
A small, condition-specific crossover trial reported sparse mild-to-moderate self-reported dizziness, headaches, and migraine across placebo and Fisetin phases; it does not establish a Fisetin-specific causal risk or apply to healthy users.
In the United States, dietary-supplement labels must avoid disease claims; FDA structure/function-claim guidance is general context, not a Fisetin-specific determination.
Interactions and cautions
The AFFIRM-LITE protocol lists holds for certain CYP-sensitive medicines, some antimicrobials, and acid-reducing medicines. Use these as protocol-specific precautionary flags when comparing products or planning stacks, not as proof of clinical interactions or a complete medication list.
Legal and regulatory status
In the United States, FDA structure/function guidance is general dietary-supplement claim context; it does not make a product-specific legal determination for Fisetin. As of 2026, avoid disease claims.
Practical buying and quality notes
- When comparing prices, convert each listing to estimated actual fisetin. A 50% extract powder, a 98% pure powder, and a 100 mg capsule can look similar in search results but deliver different active amounts per gram or serving.6
- Fisetin has bioavailability challenges, and reviews discuss formulation strategies from macro to nano approaches. View enhanced-bioavailability claims as product-specific claims that need evidence, not as a reason to ignore dose, COA, or price-per-active-mg math.6
- For powders and extracts, look for a recent lot-specific COA with identity testing, assay or standardization, heavy metals, residual solvents, microbiology where relevant, and the actual test date. Match the COA identity to Fisetin identifiers rather than accepting a marketing name alone.1
FAQ
Is Fisetin proven as an anti-aging supplement?
4No. Preclinical studies support research interest, but they do not establish human anti-aging outcomes for Fisetin supplementation.
What Fisetin dosage has been studied?
7An AFFIRM-LITE study protocol uses 20 mg/kg/day orally for 2 consecutive days. This is study context for its enrolled population, not a general supplement recommendation.
How long does Fisetin last?
11A small healthy-adult pharmacokinetic study reported a plasma half-life of 1.14 h for unformulated Fisetin and 1.51 h for the tested Hybrid-FENUMAT formulation after a single dose. That does not establish how long a consumer feels an effect, and it should not be assumed for other products.
Is Fisetin good for memory or focus?
2Direct human evidence for memory or focus benefits is lacking. The strongest rationale is indirect: flavonol biology, antioxidant/inflammatory pathways, and senolytic research, mostly outside healthy-user cognition trials.
What should I check before buying Fisetin?
1Check whether the label identifies isolated Fisetin or a standardized extract, then compare the labelled amount per serving, price per comparable unit, and product-specific quality documentation.
References
- PubChem Compound Summary for Fisetin, CID 5281614.
- Khan N, Syed DN, Ahmad N, Mukhtar H. Fisetin: a dietary antioxidant for health promotion. Antioxidants & Redox Signaling. 2013;19(2):151-162.
- Zhu Y, Doornebal EJ, Pirtskhalava T, et al. New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. Aging. 2017;9(3):955-963.
- Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28.
- Kirkland JL, Tchkonia T. Senolytic drugs: from discovery to translation. Journal of Internal Medicine. 2020;288(5):518-536.
- Szymczak J, Cielecka-Piontek J. Fisetin-In Search of Better Bioavailability-From Macro to Nano Modifications: A Review. International Journal of Molecular Sciences. 2023;24(18):14158.
- ClinicalTrials.gov. NCT03675724: AFFIRM-LITE, Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults.
- Ji J, Crespi CM, Yee L, et al. A phase II randomized placebo-controlled study of fisetin to improve physical function in breast cancer survivors: the TROFFi study rationale and trial design. Therapeutic Advances in Medical Oncology. 2026;18:17588359261424668.
- ClinicalTrials.gov. NCT06431932: Pharmacokinetics, Safety, and Efficacy of Fisetin - A Phase I and Pilot Phase IIa Study.
- U.S. Food and Drug Administration. Structure/Function Claims.
- Krishnakumar IM, Jaja-Chimedza A, Joseph A, et al. Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin orally administered in healthy individuals: a randomised double-blinded comparative crossover study. Journal of Nutritional Science. 2022;11:e74.
- ClinicalTrials.gov. NCT04210986: Senolytic Drugs Attenuate Osteoarthritis-Related Articular Cartilage Degeneration: A Clinical Trial.
- Hodgin KS, Donovan EK, Kekes-Szabo S, et al. A Placebo-Controlled, Pseudo-Randomized, Crossover Trial of Botanical Agents for Gulf War Illness: Resveratrol (Polygonum cuspidatum), Luteolin, and Fisetin (Rhus succedanea). International Journal of Environmental Research and Public Health. 2021;18(5):2483.